A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Citations Over TimeTop 1% of 2015 papers
Abstract
Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain. There is clear demand for the construction of novel ADC platforms that offer greater stability, homogeneity and flexibility. Here we describe a significant step towards a platform for next-generation antibody-based therapeutics by providing constructs that combine site-specific modification, exceptional versatility and high stability, with retention of antibody binding and structure post-modification. The relevance of the work in a biological context is also demonstrated in a cytotoxicity assay and a cell internalization study with HER2-positive and -negative breast cancer cell lines.
Related Papers
- → B7-H3/CD276: An Emerging Cancer Immunotherapy(2021)282 cited
- → New opportunities for nanoparticles in cancer immunotherapy(2018)214 cited
- → pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review(2020)95 cited
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → Nanotechnology-Based Bacterial Immunotherapy(2022)1 cited